Artivion, Inc. (AORT)
NYSE: AORT · Real-Time Price · USD
42.42
+0.38 (0.90%)
Sep 30, 2025, 3:40 PM EDT - Market open
Artivion Revenue
Artivion had revenue of $112.97M in the quarter ending June 30, 2025, with 15.26% growth. This brings the company's revenue in the last twelve months to $405.04M, up 7.44% year-over-year. In the year 2024, Artivion had annual revenue of $388.54M with 9.75% growth.
Revenue (ttm)
$405.04M
Revenue Growth
+7.44%
P/S Ratio
4.42
Revenue / Employee
$253,148
Employees
1,600
Market Cap
2.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 388.54M | 34.53M | 9.75% |
| Dec 31, 2023 | 354.00M | 40.22M | 12.82% |
| Dec 31, 2022 | 313.79M | 14.95M | 5.00% |
| Dec 31, 2021 | 298.84M | 45.61M | 18.01% |
| Dec 31, 2020 | 253.23M | -23.00M | -8.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AORT News
- 19 days ago - Artivion, Inc. (AORT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 24 days ago - Artivion to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference - PRNewsWire
- 27 days ago - Share Growth And Strong Clinical Results Continue To Support The Artivion Story - Seeking Alpha
- 7 weeks ago - Artivion, Inc. (AORT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Artivion Reports Second Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - Artivion to Participate in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results - PRNewsWire
- 4 months ago - Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock - PRNewsWire